本文關(guān)鍵詞： 普羅布考 進(jìn)展性腦梗塞 活化的部分凝血活酶時(shí)間 血漿纖維蛋白原 血液流變學(xué) 超敏c反應(yīng)蛋白 基質(zhì)金屬蛋白酶9　出處：《西南醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討普羅布考對(duì)進(jìn)展性腦梗塞患者的神經(jīng)功能恢復(fù)情況、活化部分凝血活酶時(shí)間(Activated Partial Thromboplastin Time,APTT)、纖維蛋白原(Fibrinogen,FIB)、血液流變學(xué)、超敏c反應(yīng)蛋白(Hypersensitive C-reactive Protein,hs-CRP)、基質(zhì)金屬蛋白酶9(Matrix metallopeptidase 9,MMP-9)的影響,觀察普羅布考對(duì)進(jìn)展性腦梗塞患者的治療效果,為普羅布考治療腦梗塞的臨床應(yīng)用提供一定的依據(jù)。方法:采取隨機(jī)對(duì)照試驗(yàn)設(shè)計(jì)研究方案,納入某院神經(jīng)內(nèi)科收治的80例進(jìn)展性腦梗塞患者為研究對(duì)象,經(jīng)患者知情同意且簽定知情同意書后,隨機(jī)分為研究組和對(duì)照組,每組各40例。分別對(duì)兩組患者年齡構(gòu)成、性別構(gòu)成、體重構(gòu)成、常規(guī)檢查指標(biāo)、伴發(fā)疾病情況等因素進(jìn)行統(tǒng)計(jì)學(xué)分析,均無統(tǒng)計(jì)學(xué)差異。對(duì)照組采取常規(guī)治療方案,研究組在對(duì)照組常規(guī)治療方案的基礎(chǔ)上加用普羅布考,每次0.5g,每日2次,早、晚餐時(shí)服用,分別于治療前、治療15天后、治療30天后比較兩組患者的神經(jīng)功能缺損評(píng)分、患者總的生活能力狀態(tài)分級(jí)、APTT、FIB、血液流變學(xué)、hs-CRP、MMP-9的變化情況,治療結(jié)束后比較兩組的臨床總療效,同時(shí)比較兩組間不良反應(yīng)發(fā)生情況。結(jié)果:(1)研究組患者治療后神經(jīng)功能缺損評(píng)分、患者總的生活能力狀態(tài)分級(jí)、均較治療前有改善,且治療后30天的指標(biāo)優(yōu)于治療后15天(P0.05),研究組患者在神經(jīng)功能缺損評(píng)分、患者總的生活能力狀態(tài)分級(jí)較同期對(duì)照組均有改善,均有統(tǒng)計(jì)學(xué)差異(P0.05);研究組臨床療效高于對(duì)照組(P0.05)。(2)研究組患者治療后的APTT較治療前延長(zhǎng),且APTT治療后30天較治療后15天延長(zhǎng),研究組患者治療后的APTT較對(duì)照組同期患者均升高,均具有統(tǒng)計(jì)學(xué)差異(P0.05);(3)研究組患者治療后的FIB水平較治療前降低,且治療后30天FIB水平低于治療后15天,研究組患者治療后的FIB水平較對(duì)照組同期患者均降低,均具有統(tǒng)計(jì)學(xué)差異(P0.05);(4)研究組患者治療后的血漿粘度、全血高切粘度及全血低切粘度較治療前均降低,且上述指標(biāo)治療后30天低于治療后15天,研究組患者治療后的血漿粘度、全血高切粘度及全血低切粘度較對(duì)照組同期患者均降低,均具有統(tǒng)計(jì)學(xué)差異(P0.05)。(5)研究組患者治療后hs-CRP較治療前降低,且上述指標(biāo)治療后30天低于治療后15天,研究組患者治療后hs-CRP較對(duì)照組同期患者均降低,均具有統(tǒng)計(jì)學(xué)差異(P0.05)。(6)研究組患者治療后MMP-9較治療前降低,且上述指標(biāo)治療后30天低于治療后15天,研究組患者治療后的MMP-9較對(duì)照組同期患者均降低,均具有統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:普羅布考治療對(duì)進(jìn)展性腦梗塞患者的療效顯著,能夠延長(zhǎng)APTT,降低FIB水平,降低血漿粘度、全血高切粘度及全血低切粘度、hs-CRP、MMP-9,明顯改善腦梗塞患者神經(jīng)功能缺損及生活能力狀態(tài)。
[Abstract]:Objective: to investigate the recovery of nerve function in patients with progressive cerebral infarction treated with probucol. Activated partial thromboplastin time (APTT). Fibrinogen, hemorheology, hypersensitive C-reactive Protein. Hs-CRP, matrix metalloproteinase 9 matrix metallopeptidase 9 (MMP-9). To observe the therapeutic effect of Probucol on patients with progressive cerebral infarction, and to provide some basis for the clinical application of probucol in the treatment of cerebral infarction. Eighty patients with progressive cerebral infarction admitted to a department of neurology were randomly divided into study group and control group after informed consent and informed consent was signed. Each group of 40 cases. The two groups of patients age composition, gender composition, body weight composition, routine examination indicators, accompanied by disease and other factors were statistically analyzed. There was no statistical difference. The control group was treated with routine therapy, the study group was treated with probucol on the basis of routine treatment, 0.5g per day, 2 times a day, early and dinner. Before treatment, 15 days after treatment, 30 days after treatment, the neurological impairment scores, total life ability status of patients and APTTT FIBs, hemorheology were compared between the two groups. The changes of MMP-9 in hs-CRP were compared between the two groups after the end of treatment. At the same time, the adverse reactions between the two groups were compared. Results the neurological deficit score and the total living ability status of the patients in the study group were improved after treatment. The index of 30 days after treatment was better than that of 15 days after treatment (P0.05). The patients in the study group had improved in the neurological function deficit score and the overall living ability grading of the patients compared with the control group in the same period. There was statistical difference between the two groups (P 0.05). The clinical curative effect of the study group was higher than that of the control group (P0.05. 2) the APTT after treatment in the study group was longer than that before treatment, and 30 days after the treatment with APTT was longer than 15 days after the treatment. The APTT of the study group was higher than that of the control group in the same period (P 0.05). The level of FIB in the study group after treatment was lower than that before treatment, and the level of FIB was lower at 30 days after treatment than that at 15 days after treatment. The level of FIB in the study group was lower than that in the control group (P 0.05). (4) the plasma viscosity, whole blood high shear viscosity and whole blood low shear viscosity of the patients in the study group were lower than those before treatment, and 30 days after treatment were lower than 15 days after treatment. The plasma viscosity, whole blood high shear viscosity and whole blood low shear viscosity of the patients in the study group were lower than those in the control group. The hs-CRP of study group was lower than that before treatment, and 30 days after treatment was lower than that of 15 days after treatment. The hs-CRP of the study group was lower than that of the control group in the same period, and the difference was statistically significant (P < 0.05) the MMP-9 of the study group was lower than that of the control group (P < 0.05). The MMP-9 of the study group was lower than that of the control group at 30 days after treatment and 15 days after treatment. Conclusion: Probucol treatment in patients with progressive cerebral infarction has a significant effect, can prolong APTT, reduce the level of FIB, reduce plasma viscosity. The high shear viscosity of whole blood and the low shear viscosity of whole blood hs-CRPU MMP-9 significantly improved the neurological function defect and living ability of patients with cerebral infarction.
【學(xué)位授予單位】：西南醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R743.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 秦靈芝;李瑋;楊紅旗;黃月;李書劍;張杰文;;普羅布考對(duì)急性腦梗死患者血清MMP-9及oxLDL-Ab濃度的影響[J];中國(guó)實(shí)用神經(jīng)疾病雜志;2016年19期

2 蔡永強(qiáng);;補(bǔ)中益氣湯加味聯(lián)合阿托伐他汀治療腦梗塞并高血脂的療效觀察及其對(duì)血液流變學(xué)的影響[J];中國(guó)中醫(yī)藥科技;2016年01期

3 葉長(zhǎng)安;;腦梗塞前期患者的腦血流動(dòng)力學(xué)的改變及多排CT灌注成像表現(xiàn)及分期[J];中國(guó)CT和MRI雜志;2015年12期

4 李萌生;王曉菲;宋立華;李強(qiáng)強(qiáng);劉坤;;針灸聯(lián)合西藥治療腦梗塞的療效[J];中西醫(yī)結(jié)合心血管病電子雜志;2015年30期

5 郭艷宇;;CT診斷早期腦梗塞的價(jià)值分析[J];中國(guó)衛(wèi)生標(biāo)準(zhǔn)管理;2015年11期

6 陳佳;柯生海;趙芳;吳文軍;;化痰通絡(luò)合劑合常規(guī)西藥治療腦梗塞恢復(fù)期臨床觀察[J];山西中醫(yī);2015年02期

7 吳振宏;歐陽(yáng)強(qiáng);梁儉孫;;PAS三聯(lián)療法對(duì)老年急性腦梗死患者血清高遷移率族蛋白B1、骨保護(hù)素及巨噬細(xì)胞移動(dòng)抑制因子水平的影響[J];中國(guó)老年學(xué)雜志;2015年03期

8 楊美榮;向海溶;;腦梗死進(jìn)展期應(yīng)用低分子肝素鈣與硫酸氯氫吡格雷治療的臨床分析[J];陜西醫(yī)學(xué)雜志;2014年12期

9 賀曦;王進(jìn)平;張敏;楊柳;黃艷玲;;普羅布考對(duì)急性腦梗死患者神經(jīng)功能變化及血清S100β、NSE、hs-CRP的影響[J];重慶醫(yī)學(xué);2014年30期

10 賈東佩;;降纖酶對(duì)腦梗塞急性期患者APTT、PT與血液流變學(xué)的影響[J];中國(guó)生化藥物雜志;2014年07期

，

本文編號(hào)：1445396